Technology is integral to our lives in a way that would have been inconceivable even a few decades ago. Breakthrough drugs save lives, novel materials change how we build, AI reimagines what is possible. Every day, new scientific discoveries are being made that have the potential to radically improve and enhance both our lives and the world we live in.
But discoveries in a lab don’t change the world. To realise their potential, they must first be transformed into real-world products and services which takes time, determination, and the right support.
Science Creates Ventures was founded to back exceptional teams building game changing UK-based deep tech companies with investment and qualified mentorship. We get excited by truly standout technology that has the potential to disrupt existing industries or create entirely new ones, and we love investing at the early stages of a company’s journey.
We’re a team of serial entrepreneurs, investors and scientists who have unique insight into the challenges facing young deep tech companies. We bring a hands-on, tailored approach to supporting and mentoring our portfolio companies, focusing on setting them on the best path for growth and success from the outset.
“SCV were absolutely pivotal for our fundraise. They worked with us tirelessly to pull together syndicate partners and get the deal over the line.”
“SCV were completely straight with us. They did everything they said they’d do and found solutions when things got stuck. They continue to provide constructive guidance and we highly value having them as investment partners.”
Harry is the founder of the Science Creates ecosystem and Managing Partner of Science Creates Ventures. He is a scientist, entrepreneur and investor, and the co-founder of Ziylo, the hugely successful University of Bristol spin-out company. Harry is passionate about building great companies and providing the optimum ecosystem to facilitate their growth and development.
Catherine is a lead member of the Deal Team, overseeing the investment pipeline and managing the operational aspects of the fund. Catherine’s excellent scientific credentials and wealth of academic experience makes her ideally placed to support and develop early-stage deep tech companies within the portfolio.
Laura is a member of the Deal Team and works across Science Creates Ventures’ investment pipeline. She is a Biochemist with research experience in academia and biotech. Laura has also worked across grant-funding for scientific research and is passionate about enabling opportunities for the commercialisation of scientific innovations.
Kay supports the Science Creates team with her meticulous organisation and project and event management skills. She brings over 10 years’ experience within consulting and management firms to the team. Kay is dedicated to maintaining the culture of Science Creates as the ecosystem continues to grow.
Peter provides finance support to Science Creates Ventures. He has experience as an analyst and compliance officer at an FCA-regulated private equity and EM hedge fund manager in Bristol and headed the group’s finance department. Peter has also provided support to a number of early-stage Bristol-based companies.
Charles is a respected chair, director and adviser to public and private companies in the medical technology sector with twenty-five years hard-won experience in translating innovation into commercial success and shareholder value. His past and current portfolio include: as a chair/director, Creo Medical (AIM), IXICO (AIM), MJ Hudson (AIM) and Aircraft Medical (sold to Medtronic); as an investor, Medivance (sold to CR Bard) and Stanmore Implants (sold to Stryker); and as an adviser, The Surgical Group (sale of Distribution Activities to Duomed Group), Medovate, Abcam (AIM), VisionRT (sold to William Demant), and Gyrus Group (sold to Olympus). He has reviewed over a thousand medtech innovations as chair of the NIHR’s i4i grant giving panel.
Mark has a portfolio of chairman roles in early-stage technology companies. With a background in engineering and physics, his career began at optics start-up Kymata, which was acquired by Alcatel Optronics for €120m. He then held a variety of executive roles in VC and PE backed companies. At instrumentation company Insensys, he sold the oil and gas division to Schlumberger (undisclosed – 2007) and the rest of the business to Moog ($23m – 2009). Mark has also spent 5 years as a venture capital investor. He led hardware investments at Mercia Asset Management, which grew during his time from around £90m to £900m assets under management.
Akta is a serial entrepreneur, a qualified solicitor, having qualified at Slaughter and May, and a former investment banker. She founded Enhabit, an award-winning low carbon building company, which was acquired by and absorbed into Efficient Building Services Ltd in 2020. She is a founding director of Construction Carbon, a company building software to measure embodied carbon emissions. She has created companies serving the real estate sector (Townlab, Flying Butler Apartments, The Apartment Network), procurement (4C Procurement), dentistry (ALS Dental) and edtech (Educate) sectors. These firms are managed by Ansor Ventures, which completed a £50m fundraising in 2020. She is an angel investor and an adviser to multiple venture-backed businesses. She is a chair of the digital board and finance committees at the Royal Free London Foundation Trust, Vice-Chair of the Royal Free Charity and a Trustee of BLP, a charity supporting young entrepreneurs in South London.
Jonathan is Chief Operating Officer of Circassia PLC, a medical diagnostics company, a position he had held since 2019. He has more than thirty years experience of in business leadership in the life sciences sector. Prior to joining Circassia in 2019, he worked for Pfizer (1999 to 2019) in a variety of senior leadership roles including Managing Director Pfizer UK and finally Chief Commercial Officer Pfizer Internal Medicines. At Pfizer, he led the launch of 15 products across a broad range of therapeutic areas and worked on numerous product and company transactions and executed several business turnarounds. He was elected President of the Association of the British Pharmaceutical Industry (2013-15). His interests include angel investing and supporting science-based innovation. Jonathan has a BSc in Materials Science.
Emma has been a member of Science Creates Ventures’ Advisory Panel since 2020. She is CEO of Weatherden, a leading early clinical development company, and CEO of Remedy Rx, a digital health company supporting patients with chronic disease with the aim of ultimately transforming care, research and medicines under development. She has extensive experience in R&D strategy and clinical development across multiple therapeutic areas. She has been involved in the creation of 5 biotech companies in addition to Weatherden and Remedy Rx (Artios Pharma, Sitryx Therapeutics, Enara Bio, Trex Bio, Zarodex Therapeutics). Emma qualified as an accountant at KPMG with life sciences, private equity and transactions experience before moving to SV Health Investors, a blue-chip transatlantic healthcare investor where she worked between 2015 – 2018. She initially worked on the public fund, International Biotechnology Trust (£250m – 2017) at SV Health Investors before moving to the Venture Capital team, focused on biotech company creation for a $400m fund.
John is a chartered accountant with more than 25 years experience as a Chief Financial Officer with venture capital-backed and listed companies focusing particularly on medical device and biotech companies from start-up through commercialisation. From its foundation in 2012 to his retirement in July 2021, John was the Chief Financial Officer of Syncona Investment Management Limited, the Investment Manager of Syncona Limited, a FTSE250 listed life sciences investment company which grew assets under management from £100m to £1.3bn in that period. John is a Non-Executive Director and audit committee chair of AIM listed medical device company Creo Medical Group plc.
David is one of the foremost Pharma/biotech deal makers operating in Europe. Originally qualified as a pharmacist he joined Shire in 1999 when its market cap was approx $200M, when he left his role of head of business development in 2014 it had grown to $30Bn. David led many of the deals instrumental in driving the company growth. Since leaving Shire David has split his time between a number of Board roles (Orexo, HRA Pharma, Nasdaq listed SPAC, Forendo, Oak Hill Bio) and representing biotech companies in negotiations with Pharma. His total value of deals delivered (if all milestones are reached) is over $5Bn.
Keith has over 30 years of corporate finance experience both with major financial institutions (Citibank & Lloyds Bank) and within boutique investment firms (Manresa Partners and Aspanova). As an investor, director and mentor of multiple early-stage companies, his career has included the sale of Ziylo Limited to Novo Nordisk A/S in 2018, the sale of Activate Clients to FD Technologies plc in 2015, membership of the Lloyds Development Capital Investment Committee 2009-2013, Executive Chairmanship of both Science Creates Incubators and Carbometrics Ltd plus numerous other relevant roles and experience. Keith is a Chartered Director and a Fellow of the Institute of Chartered Accountants.
David is co-founder and director of Revena, a technical consultancy and network that supports both deep tech investors and companies. He has led the technical evaluations of over 150 companies on behalf of funds with over $6bn under management. An active translational scientist, he has worked with a range of large and small companies (incl. Dow Chemical and OxSyBio) guiding research toward novel intellectual property and through product development. A former academic (Universities of Oxford, Bristol, and California), he has over 30 papers and patents and is a technical advisor to multiple science-focused companies (incl. BioFeyn, Milosensors, and Vatic Health).
Jon co-founded Science Creates Ventures in 2020 and has since played a leading role on its Advisory Panel. Jon also sits on the Board of Science Creates Ventures LLP. Jon is a seasoned tech entrepreneur with a background in software engineering and multiple exits under his belt. Jon exited his first company, Cramer, for $425m in 2006, representing an exit value to capital raised ratio of 47x. Since then, he has been an active and successful angel investor. Some notable examples include the exits of Swiftkey (undisclosed – 2016) and Zynstra ($130m – 2019). Jon was also a significant angel investor in Creo Medical, which listed on the London Stock Exchange’s growth market in 2017 (LON: CREO). A significant aspect of Jon’s success has been how he has focussed his energy on just a few companies, often playing active roles either at board level or as a mentor.
Science Creates St Philips, Albert Road, Bristol, BS2 0XJ
Science Creates Old Market, Midland Road, Bristol, BS2 0JZ
Science Creates Ventures (FRN: 933134) is an Appointed Representative of Kin Capital Partners LLP “KCP”, which is authorised and regulated by the Financial Conduct Authority (FRN: 656789).